visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours |
Data: | 2021 |
Resum: | The recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the development of specific fusion protein inhibitors, such as larotrectinib and entrectinib, have revolutionised the diagnostic and clinical management of patients presenting with tumours with these alterations. Tumours that harbour NTRK fusions are found in both adults and children; and they are either rare tumours with common NTRK fusions that may be diagnostic, or more prevalent tumours with rare NTRK fusions. To assess currently available evidence on this matter, three key Spanish medical societies (the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Pathological Anatomy (SEAP), and the Spanish Society of Paediatric Haematology and Oncology (SEHOP) have brought together a group of experts to develop a consensus document that includes guidelines on the diagnostic, clinical, and therapeutic aspects of NTRK -fusion tumours. This document also discusses the challenges related to the routine detection of these genetic alterations in a mostly public Health Care System. |
Ajuts: | Instituto de Salud Carlos III PI11/02866 Instituto de Salud Carlos III PI14/01176 Instituto de Salud Carlos III PI7/01001 Instituto de Salud Carlos III PI17/00464 |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Matèria: | Gene fusions ; Molecular oncology ; Mutations ; Neoplasm ; Target therapies |
Publicat a: | Clinical & translational oncology, Vol. 23 (february 2021) , p. 1529-1541, ISSN 1699-3055 |
13 p, 1.1 MB |